FDA Approves Ionis' Zanvastro for Alexander Disease
On September 3, 2026, the U.S. Food and Drug Administration approved Ionis Pharmaceuticals' Zanvastro (zilganersen), an antisense oligonucleotide therapy, for Alexander disease, a rare neurological disorder affecting the brain’s white matter. The approval makes Zanvastro the first disease-modifying treatment approved for Alexander disease.
Reuters directly reports that the U.S. FDA approved an Ionis Pharmaceuticals therapy for a rare condition affecting the brain’s white matter. Additional supporting context explicitly identifies the therapy as Zanvastro (zilganersen) and the condition as Alexander disease, and describes it as the first disease-modifying treatment approved for that disease; the name and description are therefore updated to include those details. This is a material, forward-looking regulatory milestone with direct commercial relevance for IONS. The provided 20:02:24 timestamp appears to be the source publication time rather than the actual approval time, so the occurrence is date-normalized to September 3, 2026 at 00:00 UTC with limited confidence in the exact time. Indirect payers, distributors, CDMOs, packaging suppliers, and other companies are excluded because no event-specific relationship or confirmed economic impact is disclosed.
The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' NASDAQ:IONS therapy to treat a rare condition that affects the brain's white matter.